It remains unclear whether similar CR rates and the optimal prognosis of MS with the CBFβ/MYH11 fusion can be predicted based on the current data concerning AML with the CBFβ/MYH11 fusion. This evidence concerns the gene MYH11 and acute myeloid leukemia.